Article

Topical NSAID dosed b.i.d. effectively treats macular edema following cataract surgery

Fort Lauderdale, FL-The new b.i.d. dosed topical non-steroidal anti-inflammatory drug (NSAID) bromfenac ophthalmic solution 0.09% (Xibrom, Ista Pharmaceuticals), was found to be as effective as either diclofenac sodium 0.1% ophthalmic solution (Voltaren, Novartis Ophthalmics) or ketorolac tromethamine 0.5% (Acular, Allergan) ophthalmic solution dosed q.i.d. in a recent study of acute pseudophakic cystoid macular edema (CME) treatment following uncomplicated cataract surgery.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.